All In Biotech

Drug Trial Radar · NCT06096337

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 484 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

484

Actual

Start

Dec 28, 2023

Primary completion

Feb 4, 2026

Study completion Feb 4, 2028

Sponsor

Lead sponsor
Boston Scientific CorporationIndustry
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

Conditions

  • Persistent Atrial Fibrillation

Interventions

  • FARAPULSE™ Pulsed Field Ablation (PFA) SystemDevice

    Subjects will undergo a pulsed field ablation procedure using the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins and posterior wall.

  • Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and DronedaroneDrug

    Anti-Arrhythmic Drugs (AADs) including, Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone will be prescribed and monitored in accordance with local clinical practice and already established guideline-directed therapy for patients with persistent atrial fibrillation (AF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of randomized PFA or PFA Assigned subjects with PFA System inserted into the body, during the index or repeat PFA procedure during blanking period, with device or procedure-related Composite Adverse Events that is serious.Time frame: 12-Months
  2. Rate of intent to treat subjects with treatment success from the pulse field ablation treatment and Anti-Arrhythmic Drug treatment.Time frame: 12-Months

Locations

61 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Banner University Medical Center Phoenix

    Phoenix, Arizona

  • Phoenix Cardiovascular Research Group

    Phoenix, Arizona

  • Arrhythmia Research Group

    Jonesboro, Arkansas

  • Scripps Memorial Hosptial

    La Jolla, California

  • Stanford University Medical Center

    Palo Alto, California

  • Cardiology Associates Medical Group, Inc

    Ventura, California

  • HCA Florida Mercy Hospital

    Miami, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Tallahassee Memorial Hospital

    Tallahassee, Florida

  • St. Joseph's Hospital

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Memorial Health University Medical Center

    Savannah, Georgia

  • St. John's Hospital

    Springfield, Illinois

  • Community Heart and Vascular Hospital

    Indianapolis, Indiana

  • Mercy Hospital Medical Center-Hospital

    West Des Moines, Iowa

  • Baptist Health Lexington

    Lexington, Kentucky

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Southcoast Physicians Group

    Fall River, Massachusetts

  • University of Michigan Hospitals

    Ann Arbor, Michigan

  • Corewell Health

    Grand Rapids, Michigan

  • Mayo Clinic Foundation-Hospital

    Rochester, Minnesota

  • Catholic Medical Center

    Manchester, New Hampshire

  • Valley Hospital

    Paramus, New Jersey

  • Northwell Health

    Bay Shore, New York

  • Kaleida Health

    Buffalo, New York

  • Weill Cornell Medical University

    New York, New York

  • Good Samaritan - Suffern

    Suffern, New York

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Bethesda North Hospital

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • OhioHealth Research and Innovation Institute - Riverside Methodist Hospital

    Columbus, Ohio

  • Oklahoma Heart Institute

    Tulsa, Oklahoma

  • York Hospital

    York, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Medical Branch

    Galveston, Texas

  • Orion Medical

    Houston, Texas

  • Christus Trinity Mother Frances Health System

    Tyler, Texas

  • Intermountain Medical Center

    Murray, Utah

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.